Currently submitted to: JMIR Dermatology
Date Submitted: Mar 8, 2026
Open Peer Review Period: Mar 12, 2026 - May 7, 2026
(currently open for review)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Agentic AI in Dermatology: A Call to Action
ABSTRACT
Artificial intelligence tools are shifting from passive, user-initiated tools to proactive agentic AI systems that are capable of autonomous, multi-step actions. These agents can independently gather information, execute sequential tasks, and collaborate with humans or other agents without requiring constant prompting from humans. Early adopters in healthcare have demonstrated early feasibility across multiple specialties and clinical settings. Dermatology is well-positioned to benefit given its high patient volumes, administrative burdens, and clinicopathological workflow. To guide responsible adoption of agentic AI, we propose a risk-stratification framework based on clinical risk and task reversibility. Barriers to widespread adoption of agentic AI include limitations in model reliability, interoperability across health records, and unresolved questions around liability, privacy, and regulation. Dermatologists must proactively engage via professional organizations and industry partnerships to ensure that agentic AI is developed safely, equitably, and in alignment with our values.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.